Kidney Biopsy Industry to Witness 5.4% Growth, Reaching $2.8 Billion by 2029

 

The kidney biopsy market size has grown strongly in recent years. It will grow from $2.14 billion in 2024 to $2.27 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%.  The growth in the historic period can be attributed to increased chronic kidney diseases, rise in awareness about early diagnosis, surge in geriatric population, expansion of healthcare infrastructure, enhanced government initiatives for kidney disease management, and rise in awareness of kidney health.

The kidney biopsy market size is expected to see strong growth in the next few years. It will grow to $2.8 billion in 2029 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to increasing prevalence of kidney diseases, rising healthcare expenditure, growing awareness about early diagnosis, expanding geriatric population, rising demand for minimally invasive procedures, and increasing research activities. Major trends in the forecast period include technological advancements in biopsy techniques, adoption of minimally invasive procedures, advancements in imaging technologies, integration of artificial intelligence for better precision, and technological innovations in biopsy devices.

 

Get Your Free Sample of The Global Kidney Biopsy Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16458&type=smp

What have been the primary factors driving the kidney biopsy market’s growth?
The rise in the incidence of renal cancer is expected to propel the growth of the kidney biopsy market going forward. Renal cancer is characterized by the uncontrolled growth of abnormal kidney cells. The rise in renal cancer is attributed to factors such as changes in lifestyle, environmental toxins, and better detection techniques that result in more diagnoses. A kidney biopsy helps diagnose and manage renal cancer by confirming the presence of cancerous cells, determining cancer grade, planning treatment, monitoring treatment response, and providing prognostic information. For instance, according to Cancer Research UK, a UK-based cancer research organization, the new kidney cancer cases are expected to increase from approximately 16,300 in 2023 to about 21,900 in 2025. Therefore, the rise in the incidence of renal cancer is driving the growth of the kidney biopsy market.

What are the key segments within the kidney biopsy market?
The kidney biopsy market covered in this report is segmented –
1) By Type: Percutaneous Biopsy, Surgical Biopsy
2) By Indication: Kidney Failure, Kidney Transplant, Hematuria, Proteinuria
3) By End-User: Hospitals And Clinics, Urology Centers, Tertiary Care Centers, Other End-Users

Subsegments:
1) By Percutaneous Biopsy: Ultrasound-Guided Biopsy, CT-Guided Biopsy, MRI-Guided Biopsy
2) By Surgical Biopsy: Open Kidney Biopsy, Laparoscopic Kidney Biopsy

Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/kidney-biopsy-global-market-report

Which key players are shaping the kidney biopsy market?

Major companies operating in the kidney biopsy market are Cardinal Health, Pfizer Inc., Merck & Co. Inc., Thermo Fisher Scientific Inc., AstraZeneca, Medtronic, Siemens Healthcare Private Limited, Becton, Dickinson and Company, Stryker Healthcare, Baxter International Inc., Boston Scientific Corporation, F. Hoffmann-La Roche Ltd., Zimmer Biomet, Agilent Technologies Inc., Olympus Corporation, Hitachi High-Tech Corporation, Beckman Coulter Inc., B. Braun, Sysmex Corporation, Cook Medical, Bio-Rad Laboratories Inc., Integra LifeSciences Corporation, Merit Medical Systems, Leica Biosystems Nussloch GmbH, Argon Medical Devices Inc., BioGenex

How will emerging trends drive the kidney biopsy market throughout the forecast period?
Major companies operating in the kidney biopsy market are developing innovative platforms by integrating with artificial intelligence (AI) to enhance diagnostic accuracy, streamline procedures, and improve patient outcomes. Artificial intelligence (AI) enhances kidney biopsy by improving image analysis, providing diagnostic support, aiding in treatment planning, offering predictive analytics, and advancing research in kidney diseases. For instance, in March 2024, Aiosyn, a Netherlands-based software company, launched the NephroPath platform. The NephroPath platform uses computational pathology algorithms to analyze histological biomarkers in kidney biopsies, including identifying tissue types, measuring interstitial fibrosis, and precisely counting and assessing glomeruli. This AI-driven analysis ensures consistent, detailed, and reproducible scoring of renal pathology biomarkers, overcoming the drawbacks of traditional scoring methods and observer subjectivity.

How do regional factors impact the kidney biopsy market, and which region is the largest contributor?

North America was the largest region in the kidney biopsy market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney biopsy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Does The Kidney Biopsy Market Report 2025 Offer?
The kidney biopsy market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.

A kidney biopsy, also known as a renal biopsy, is a medical procedure in which a small piece of kidney tissue is removed for microscopic examination. This procedure is typically performed to diagnose kidney conditions, assess the severity of known kidney diseases, or monitor the effectiveness of treatment. A kidney biopsy can help identify various kidney disorders, such as glomerulonephritis, interstitial nephritis, and nephrotic syndrome, and provide valuable information on the underlying causes of kidney dysfunction.

Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16458

About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.

Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Comments

Post a Comment

Popular posts from this blog

Global Antiepileptic Drugs Market Forecast Highlights Growth Outlook And Key Trends Over 2026–2030

Image
  The antiepileptic drugs market size has grown strongly in recent years. It will grow from $17.83 billion in 2025 to $18.74 billion in 2026 at a compound annual growth rate (CAGR) of 5.1%. The growth in the historic period can be attributed to epilepsy prevalence growth, first-generation drug reliance, hospital neurology expansion, seizure disorder awareness, generic drug penetration. The antiepileptic drugs market size is expected to see strong growth in the next few years. It will grow to $22.87 billion in 2030 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to treatment-resistant epilepsy management, novel AED approvals, personalized neurology care, pediatric epilepsy diagnosis, long-acting formulations. Major trends in the forecast period include shift toward third-generation AEDs, growing use of combination therapy, expansion of pediatric epilepsy management, increased adoption of long-term seizure control, growth of gene...
Read more

Global Haptic Virtual Reality (VR) Fitness Suit Market Analysis Highlights Emerging Opportunities And Revenue Forecasts Through 2030

Image
  The haptic virtual reality (vr) fitness suit market size has grown exponentially in recent years. It will grow from $1.6 billion in 2025 to $2.05 billion in 2026 at a compound annual growth rate (CAGR) of 27.7%. The growth in the historic period can be attributed to rising popularity of virtual fitness applications, increasing consumer interest in immersive workouts, growth of wearable fitness technologies, expansion of home-based fitness solutions, improvements in haptic hardware capabilities. The haptic virtual reality (vr) fitness suit market size is expected to see exponential growth in the next few years. It will grow to $5.4 billion in 2030 at a compound annual growth rate (CAGR) of 27.4%. The growth in the forecast period can be attributed to increasing adoption of ai-driven fitness personalization, rising demand for remote and virtual training solutions, expansion of rehabilitation and therapeutic vr applications, growing integration of biometric feedback systems, advan...
Read more

2025 Strategic Guide to the Drugs For Benign Prostatic hypertrophy Market – Forecasts and Business Use Cases

Image
  The drugs for benign prostatic hypertrophy market size has grown strongly in recent years. It will grow from $4.28 billion in 2024 to $4.58 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to aging population, increased awareness, advancements in drug therapies, healthcare access. The drugs for benign prostatic hypertrophy market size is expected to see strong growth in the next few years. It will grow to $5.58 billion in 2029 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to emerging markets, new drug developments, increasing awareness and education, regulatory approvals. Major trends in the forecast period include minimally invasive treatments, personalized medicine, combination therapies, patient-centered care, telemedicine and digital health, research and development. #Download Your Free Sample PDF:# https://www.thebusinessresearchcompany.com/sample.a...
Read more